Latest Insulin pen Stories
Enter today for a chance to win a trip to the 2013 IndyCar® Series finale BIRMINGHAM, Ala., April 5, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and IZOD IndyCar Series driver Charlie Kimball today kicked off a new contest asking people to support Charlie by encouraging their friends and family to join the Race with Insulin(®) crew. Now through September 15, by sharing Kimball's story about the importance of team support with two or more friends or family,...
PRINCETON, N.J., Jan. 22, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog(®) Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog(®) (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they're giving back to their local communities. To view the multimedia assets associated with this release, please click:...
PARIS, France, June 11, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States, providing further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus® (insulin glargine [rDNA...
PRINCETON, N.J., May 22, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. With the expansion of its pediatric indication, Levemir(®) is now available for type 1 diabetes patients from age two through adulthood and adult patients with type 2 diabetes. To view the...
PRINCETON, N.J., April 9, 2012 /PRNewswire/ -- Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza(®) (liraglutide [rDNA origin] injection) to include data showing superior blood sugar control when compared to Januvia(®) (sitagliptin). Victoza(®) also provided greater weight reduction. Both products were taken in combination with metformin in adults with type 2 diabetes. To view the multimedia assets...
PRINCETON, N.J., April 2, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for a pregnancy Category B classification, indicating that Levemir(®), when used in pregnant women with diabetes, did not increase the risk of harm to the unborn baby. To view the multimedia assets associated with this release, please click:...
PRINCETON, N.J., Jan. 19, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), the world leader in diabetes care, has been ranked 43rd in FORTUNE magazine's 2012 "100 Best Companies to Work For" list. Reflecting the passion of Novo Nordisk's employees, the company has been highlighted on the list for four consecutive years. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO ) "I'm convinced that it is our people who set us apart. Each and every person at Novo Nordisk...
DUSSELDORF, Germany, December 19, 2011 /PRNewswire/ -- - Growth in demand for pharmaceutical and medical plastic systems - Gerresheimer invests around EUR 25 million in its Pfreimd plant - 130 new jobs Gerresheimer AG, one of the world's leading suppliers to the pharma and healthcare industry, further invests in the growth market of complex plastic systems for pharmaceutical and medical applications. Production capacity is being...
PRINCETON, N.J. and INDIANAPOLIS, Ind., Nov. 15, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams, Inc. announced today that the two organizations have entered into a multi-year extension of their partnership. Novo Nordisk will remain the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. To view the multimedia assets associated with this release, please click:...
FRANKLIN LAKES, N.J., Oct. 31, 2011 /PRNewswire/ -- BD AutoShield(TM) Duo is a next generation, 5mm safety-engineered pen needle designed to protect healthcare workers from needlestick injuries and blood exposure. It is now available in the US from BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company. To view multimedia assets for this release, please click:...
